Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 3/20 | 0.35 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL10333356 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL30623538 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL5311978 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL19031715 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL29417354 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL8370309 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL35445 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL9446378 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL263268 | 1.00 | TSHR (0.67) | TSHRLMNACYP3A4TDP1BLM | |
| Cadaverine Tartrate SCHEMBL5665118 | 0.97 | TSHR (0.62) | TSHRLMNACYP3A4TDP1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1394 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114246953-B | Anti-cMet antibody drug conjugates and methods of use thereof | 艾伯维生物制药股份有限公司 | 2024-07-09 | — | — | CN | claimed |
| US-20210171573-A1 | IMPROVED PROTEIN RECOVERY | BRISTOL-MYERS SQUIBB COMPANY | 2021-06-10 | — | — | US | claimed |
| CN-112566920-A | Improved protein recovery | 百时美施贵宝公司 | 2021-03-26 | — | — | CN | claimed |
| EP-4673463-A2 | MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673470-A2 | MULTISPECIFIC MOLECULES COMPRISING A PEPTIDE-MHC COMPLEX COMPRISING AN MHC DOMAIN AND AN ANTIGENIC PEPTIDE AND AN IMMUNE CELL ANTIGEN TARGETING MOIETY | Regeneron Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025245494-A1 | TUMOR-TARGETED SPLIT IL12 RECEPTOR AGONISTS | REGENERON PHARMACEUTICALS, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4573110-A1 | INTERFERON PROPROTEINS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2025122817-A1 | ANTAGONISTIC CD40 ANTIBODIES | THE GENERAL HOSPITAL CORPORATION (US) | 2025-06-12 | — | — | WO | disclosed |
| WO-2025111553-A2 | ANTIBODY-BASED HUMAN LAMP-1 COMPOSITION AND ITS USES | THE GENERAL HOSPITAL CORPORATION (US) | 2025-05-30 | — | — | WO | disclosed |
| WO-2025106469-A1 | ENGINEERED HEAVY CHAIN VARIABLE DOMAINS AND USES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4536690-A1 | INTERLEUKIN-2 PROPROTEINS AND USES THEREOF | Regeneron Pharmaceuticals, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-0386106-A1 | GAMMA INTERFERON FORMULATION. | GENENTECH INC (US) | 1990-09-12 | — | — | EP | disclosed |
| WO-1989007945-A1 | HUMAN RELAXIN FORMULATION | GENENTECH, INC. (US) | 1989-09-08 | — | — | WO | disclosed |
| WO-1989004177-A1 | GAMMA INTERFERON FORMULATION | GENENTECH, INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0284249-A1 | Lyophilized lymphokine composition | INTERFERON SCIENCES, INC. (US) | 1988-09-28 | — | — | EP | disclosed |
| US-4675184-A | VIRICIDES | 501 Sunstar Kabushiki Kaisha (JP) | 1987-06-23 | — | — | US | disclosed |
| EP-0080879-B1 | PHARMACEUTICAL COMPOSITION CONTAINING INTERFERON IN STABLE STATE | SUNSTAR KABUSHIKI KAISHA (JP) | 1986-10-01 | — | — | EP | disclosed |
| US-4605555-A | INTERFERON, POLYHYDRIC SUGAR ALCOHOL, ORGANIC ACID BUFFER | SUN STAR KABUSHIKI KAISHA (JP) | 1986-08-12 | — | — | US | disclosed |
| US-4605556-A | APPLYING INTERFERON, POLYHYDRIC SUGAR ALCOHOL, AND ORGANIC ACID BUFFER | SUN STAR KABUSHIKI KAISHA (JP) | 1986-08-12 | — | — | US | disclosed |
| EP-0080879-A2 | Pharmaceutical composition containing interferon in stable state | SUNSTAR KABUSHIKI KAISHA (JP) | 1983-06-08 | — | — | EP | disclosed |